Genedx outlines Q4 revenue of at least $135M while raising 2026 adjusted net income guidance to at least $12M

• “Our Q3 results reflect profitable execution in a growing market,” Katherine Stueland (CEO & Director) said, highlighting “$123.1 million in total revenue,” “adjusted gross margin to 72%,” “adjusted net income of $8.6 million,” and “over 32,100 exome and genome tests.”

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.